EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Treatment Patterns, Healthcare Resource Utilization, and Costs Among Patients Diagnosed With Locally Advanced/Metastatic Urothelial Carcinoma Prior to Receiving Enfortumab Vedotin: A Real‐World Evidence Study

Alicia K Morgans, Lisa Mucha, Christina Quicquaro, Vanessa Shih, Bin Xie, Christopher Young, Hongbo Yang, Qing Liu, Alexandra Greatsinger, Angela Lax

International Journal of Urology · 2025

DOI: 10.1111/iju.70023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Urology, 2025. Verfasst von Alicia K Morgans und 9 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Antibodies, Monoclonal, Patient Acceptance of Health Care. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Seagen, Astellas Pharma Inc., Astellas Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To describe real‐world patient characteristics, prior treatment patterns, and associated healthcare resource utilization (HRU) and costs among patients with locally advanced/metastatic urothelial carcinoma (la/mUC) treated with enfortumab vedotin (EV).

Methods

This retrospective study used the United States (US) Centers for Medicare and Medicaid Services 100% Medicare claims data from 2015 to 2020. Included patients had a diagnosis of la/mUC and received treatment with EV. The index date was the EV initiation date. Endpoints included HRU and costs 12 months before the index date (baseline period) and treatment patterns before EV initiation. Results were summarized descriptively using means and standard deviations for continuous variables, and frequency counts and percentages for categorical variables.

Results

Among the 529 included patients, the mean age at the time of EV initiation was 76.5 years. Most patients were White (88.1%) and male (77.1%). Common comorbidities were hypertension (85.1%), renal disease (65.2%), and peripheral vascular disease (42.5%). Platinum‐based chemotherapy was the most frequent therapy two lines before EV initiation (43.9%). The most frequent therapy in the line before EV initiation was PD‐1/L1 inhibitors (61.4%). The median duration of EV therapy was 4.1 months. The mean all‐cause healthcare cost during the baseline period was $106 258 per patient, and 86% had at least one outpatient visit.

Conclusions

This real‐world study demonstrated that most US patients with la/mUC received platinum‐based chemotherapy or a PD‐1/L1 inhibitor prior to EV therapy from 2015 to 2020. HRU and costs 12 months before EV initiation suggest a substantial burden in this population. Long‐term studies with more recent data are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Transitional CellUrinary Bladder NeoplasmsAntibodies, MonoclonalPatient Acceptance of Health CareHealth Care CostsHumansMaleRetrospective StudiesFemaleAgedUnited StatesAged, 80 and overMedicareHealth Resources

Stichwörter der Autor:innen

enfortumab vedotinhealthcare costsmetastatic urothelial carcinomaretrospective studytreatment patterns

Substanzen

enfortumab vedotinAntibodies, Monoclonal

Autor:innen und Institutionen

  • Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Astellas Pharma, Inc., Northbrook, Illinois, USA.
  • Pfizer, New York, New York, USA.
  • Analysis Group, Boston, Massachusetts, USA.
  • Analysis Group, New York, New York, USA.

Förderung

  • Seagen
  • Astellas Pharma Inc.
  • Astellas Pharma

Zitieren

APA

Morgans, A. K., Mucha, L., Quicquaro, C., Shih, V., Xie, B., Young, C., Yang, H., Liu, Q., Greatsinger, A., & Lax, A. (2025). Treatment Patterns, Healthcare Resource Utilization, and Costs Among Patients Diagnosed With Locally Advanced/Metastatic Urothelial Carcinoma Prior to Receiving Enfortumab Vedotin: A Real‐World Evidence Study. International Journal of Urology. https://doi.org/10.1111/iju.70023

Vancouver

Morgans AK, Mucha L, Quicquaro C, Shih V, Xie B, Young C, et al. Treatment Patterns, Healthcare Resource Utilization, and Costs Among Patients Diagnosed With Locally Advanced/Metastatic Urothelial Carcinoma Prior to Receiving Enfortumab Vedotin: A Real‐World Evidence Study. International Journal of Urology. 2025. doi:10.1111/iju.70023

BibTeX
@article{Morgans2025,
  author = {Morgans, Alicia K and Mucha, Lisa and Quicquaro, Christina and Shih, Vanessa and Xie, Bin and Young, Christopher and Yang, Hongbo and Liu, Qing and Greatsinger, Alexandra and Lax, Angela},
  title = {Treatment Patterns, Healthcare Resource Utilization, and Costs Among Patients Diagnosed With Locally Advanced/Metastatic Urothelial Carcinoma Prior to Receiving Enfortumab Vedotin: A Real‐World Evidence Study},
  journal = {International Journal of Urology},
  year = {2025},
  doi = {10.1111/iju.70023}
}
Kostenlos starten →